获取途径

作者

Ligang Xing Gang Wu Luhua Wang Jiancheng Li Jianhua Wang Zhiyong Yuan Ming Chen Yaping Xu Xiaolong Fu Zhengfei Zhu You Lu Chun Han Tingyi Xia Conghua Xie Guang Li Shenglin Ma Bing Lu Qin Lin Jinming Yu

作者单位

¹⁶Department of Radiation Oncology, First Affiliated Hospital of Xiamen University, Xiamen, China ¹⁷Department of Radiation Oncology, Beijing Cancer Hospital, Beijing, China ¹⁴Department of Oncology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China ¹⁵Department of Radiation Oncology, Guizhou Cancer Hospital, Guiyang, China ¹²Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China ¹³Department of Radiation Oncology, First Hospital of China Medical University, Shenyang, China ¹⁰Department of Thoracic Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China ¹¹Department of Radiation Oncology, Air Force General Hospital, Beijing, China ¹⁸Department of Radiation Oncology, PLA General Hospital, Beijing, China ⁹Department of Thoracic Oncology, Huaxi Hospital, Sichuan University, Chengdu, China ⁶Department of Radiation Oncology, CyberKnife Center, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin, China ⁵Department of Radiation Oncology, Zhengzhou University Cancer Hospital, Zhengzhou, China ⁸Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China ⁷Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China ²Cancer Center, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China ¹Department of Radiation Oncology and Shandong Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China ⁴Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Clinical College of Fujian Medical University, Fuzhou, China ³Department of Radiation Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

刊名

International Journal of Radiation Oncology*Biology*Physics

年份

2021

卷号

Vol.109 No.5

页码

1349-1358

ISSN

0360-3016

关键词

non–small-cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitors concurrent chemoradiotherapy locally advanced

摘要

Purpose This study aimed to compare erlotinib and etoposide/cisplatin with concurrent radiotherapy for patients with stage IIIA/B unresectable advanced non–small-cell lung cancer with activating epidermal growth factor receptor mutation . Methods and patients: This was a multicenter, randomized, open-label, phase 2 trial conducted across 19 institutions in China . Enrolled patients were randomized to E+RT or EP+RT . The primary endpoint was progression-free survival . Secondary endpoint...更多

Purpose This study aimed to compare erlotinib and etoposide/cisplatin with concurrent radiotherapy for patients with stage IIIA/B unresectable advanced non–small-cell lung cancer with activating epidermal growth factor receptor mutation . Methods and patients: This was a multicenter, randomized, open-label, phase 2 trial conducted across 19 institutions in China . Enrolled patients were randomized to E+RT or EP+RT . The primary endpoint was progression-free survival . Secondary endpoints included objective response rate and safety. Results A total of 252 patients were screened and 20 patients with EGFRm+ in each group received the allocated E+RT or EP+RT treatment. Patient characteristics were well-balanced between groups. Compared with EP+RT, median PFS with E+RT was significantly longer . ORR in the E+RT and EP+RT groups was 70% and 61.9%, respectively . The incidence of adverse events was similar between E+RT and EP+RT groups . Conclusions The primary endpoint of PFS was met, and the data showed that E+RT might provide PFS improvement compared with EP+RT, with similar tolerability. However, definitive statements regarding the efficacy of concurrent E+RT in patients with unresectable stage III NSCLC with activating EGFRm+ cannot be made, and slow patient accrual will likely make it infeasible to conduct a phase 3 study.收起

文献类型

期刊